The Toronto-Dominion Bank (TD) RBC Capital Markets Canadian Bank CEO Conference (Transcript)
https://seekingalpha.com/article/4662017-toronto-dominion-bank-td-rbc-capital-markets-canadian-bank-ceo-conference-transcript?source=feed_sector_transcripts
Jan 09, 2024 - The Toronto-Dominion Bank (NYSE:NYSE:TD) RBC Capital Markets Canadian Bank CEO Conference January 9, 2024 1:20 PM ETCompany ParticipantsBharat Masrani -...
0
TD Bank Group reports unsolicited mini-tender offer by TRC Capital Investment
https://seekingalpha.com/news/4054864-td-bank-group-reports-unsolicited-mini-tender-offer-by-trc-capital-investment?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news
Jan 12, 2024 - TD Bank Group receives unsolicited mini-tender offer by TRC Capital Investment to purchase 1.5M TD common shares at a 4.3% lower price, which the company...
0
Telephone and Data Systems, Inc. (TDS) Q4 2023 Earnings Call Transcript
https://seekingalpha.com/article/4671101-telephone-and-data-systems-inc-tds-q4-2023-earnings-call-transcript?source=feed_sector_transcripts
Feb 16, 2024 - Telephone and Data Systems, Inc. (NYSE:NYSE:TDS) Q4 2023 Earnings Conference Call February 16, 2024 10:00 AM ETCompany ParticipantsColleen Thompson - VP,...
0
TD Cowen ups Stoke to buy on updated data for epilepsy drug
https://seekingalpha.com/news/4083718-td-cowen-ups-stoke-to-buy-on-updated-data-for-epilepsy-drug?source=feed_sector_healthcare
Mar 26, 2024 - TD Cowen upgraded Stoke Therapeutics (STOK) to buy based on updated Phase 1/2 data for the company’s epilepsy drug candidate STK-001. Read more here.
0
TD Bank: Now Is A Good Time To Buy This 5%-Yielding Blue-Chip Deal
https://seekingalpha.com/article/4681247-td-bank-good-time-to-buy-5-percent-yielding-blue-chip-deal?source=feed_all_articles
Mar 29, 2024 - TD Bank's financial position is vigorous enough to earn upper investment-grade credit ratings from the three major rating agencies. Read why I rate TD stock a buy.
0
TD Cowen says sickle cell therapies may get higher CMS payments
https://seekingalpha.com/news/4089805-td-cowen-says-sickle-cell-therapies-may-get-higher-cms-payments?source=feed_sector_healthcare
Apr 15, 2024 - TD Cowen said recently approved gene therapies by Vertex (VRTX)/CRISPR (CRSP) and bluebird bio (BLUE) may get enhanced payments under proposed CMS guidelines. Read more here.
0
3 Incredibly Cheap High-Yield Bank Stocks to Buy Now
https://www.fool.com/investing/2024/01/28/3-incredibly-cheap-high-yield-bank-stocks-to-buy/?source=iedfolrf0000001
Jan 28, 2024 - The yields on this trio of Canadian banks are near their highest levels of the past decade. The problems they face aren't that bad.
0
TD Cowen cuts Immuneering to market perform, cites Phase 1 data
https://seekingalpha.com/news/4080047-td-cowen-cuts-immuneering-to-market-perform-cites-phase-1-data?source=feed_sector_healthcare
Mar 15, 2024 - TD Cowen has downgraded Immuneering (IMRX) to market perform, citing disappointing data from the company’s Phase 1 study for IMM-1-104 in treating solid tumors. Read more here.
0
The Toronto-Dominion Bank (TD) Q4 2023 Earnings Call Transcript
https://seekingalpha.com/article/4655308-toronto-dominion-bank-td-q4-2023-earnings-call-transcript?source=feed_sector_transcripts
Nov 30, 2023 -
0
Will Telephone & Data Systems (TDS) Report Negative Q4 Earnings? What You Should Know
https://www.zacks.com/stock/news/2223428/will-telephone-data-systems-tds-report-negative-q4-earnings-what-you-should-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2223428
Feb 08, 2024 - TDS (TDS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
0
Pages: 12
Page 1